TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20718183
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (0.3 g/kg/day for seven days)
Study: 14636103
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate supplementation (30 g/day for the first 2 weeks, 15 g/day for the final 2 weeks)
Study: 11276624
Drug: High-dose IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFN alpha-2b
Study: 11276624
Drug: Low-dose IFN
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IFN alpha-2b
Study: 6404192
Drug: DSCG (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSCG (20 mg)
Study: 28710229
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of antibiotic therapy
Study: 28768848
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (specific agents not detailed, but includes aspirin-clopidogrel)
Study: 25111348
Drug: Multisource phase-controlled
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multisource phase-controlled radiofrequency (MPCRF) treatment on the treated side of the face
Study: 15031778
Drug: pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone 45 mg once daily
Study: 15031778
Drug: acarbose 300
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acarbose 300 mg/day (3 equal doses)
Study: 10450615
Drug: Supportive psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive psychotherapy (SPT) plus antidepressant medication
Study: 10450615
Drug: Medication-alone condition
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-alone condition
Study: 2232453
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) + potassium-sparing diuretics (double doses)
Study: 28349578
Drug: Clinical pharmacist
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacist intervention providing pharmaceutical care services and close collaboration with physicians.
Study: 27604812
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and parenteral antibiotics
Study: 27604812
Drug: Rectal surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal surgery
Study: 21950458
Drug: Carbamazepine (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (100mg three times daily for 7 days)
Study: 11476257
Drug: Heroin (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin (2% solution)
Study: 11476257
Drug: Morphine (3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (3% solution)
Study: 9609749
Drug: ISIS 2302
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 2302 (0.5, 1, or 2 mg/kg)
Study: 2457072
Drug: Microsphere pancreatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microsphere pancreatic enzyme preparations (Pancrease, Creon)
Study: 2457072
Drug: Conventional enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional enzyme preparation (Pancrex V Forte)
Study: 2457072
Drug: Microsphere pancreatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microsphere pancreatic enzyme preparations (Pancrease, Creon, pancreatin Merck)
Study: 2457072
Drug: Microsphere pancreatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microsphere pancreatic enzyme preparations (Creon)
Study: 201592
Drug: Steroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid therapy after clinical deterioration
Study: 27056686
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) × 2 doses
Study: 27056686
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) single dose
Study: 27056686
Drug: Ozone ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone × 4 doses
Study: 25543089
Drug: Interferon beta-1b
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1b (IFNβ) treatment
Study: 21859185
Drug: CBT +
Normalized name: Cannabidiol
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBT + BWL (sequential treatment)
Study: 16702981
Drug: Amlodipine (A)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine (A) + Lisinopril (L)
Study: 15084389
Drug: Cisplatin +
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin + vinorelbine 25 mg/m2 days 1, 8 and 15
Study: 15084389
Drug: Cisplatin +
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin + gemcitabine 1000 mg/m2 days 1, 8 and 15
Study: 15084389
Drug: Cisplatin +
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin + paclitaxel 200 mg/m2 day 1 iv over 1h
Study: 15084389
Drug: Cisplatin +
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin + etoposide 100 mg/m2 po days 1-6
Study: 7889961
Drug: Cefprozil, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil, given once or twice daily
Study: 7889961
Drug: Cefaclor, amoxicillin‐clavulanate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor, amoxicillin‐clavulanate, or erythromycin
Study: 2606428
Drug: Colchicine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1.0 mg
Study: 2606428
Drug: Colchicine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1.5 mg
Study: 26115189
Drug: Continuous adductor
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous adductor canal block (2‐day ropivacaine 0.2% infusion)
Study: 26115189
Drug: Continuous femoral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous femoral nerve block (2‐day ropivacaine 0.2% infusion)
Study: 16953000
Drug: Tryptophan depletion
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan depletion (TD) induced by administration of capsules containing an amino acid mixture without tryptophan.
Study: 16953000
Drug: Sham depletion
Normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham depletion using identical capsules containing lactose.
Study: 15575909
Drug: Alfacalcidol 0.25
Normalized name: alfacalcidol 0.25 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol 0.25 microg daily
Study: 11685731
Drug: Docetaxel alone
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel alone (30 mg/m² intravenously, every 7 days for 3 weeks)
Study: 11685731
Drug: Docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel plus thalidomide (200 mg at bedtime)
Study: 7947128
Drug: Personal medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal medication record card
Study: 3283061
Drug: Nicardipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (30 mg, three times a day)
Study: 3283061
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 mg, three times a day)
Study: 24215485
Drug: Fixed-dose ZDV/3TC/abacavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose ZDV/3TC/abacavir (TZV)
Study: 20435936
Drug: Midazolam (0.035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.035 to 0.05 mg x kg(‐1) IV for 1 minute followed by an infusion of 0.035 to 0.05 mg x kg(‐1) x h(‐1) for 59 minutes)
Study: 20435936
Drug: Midazolam with
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam with propofol (target‐controlled infusion of propofol at constant C(T): 0.6 or 1.0 microg x mL(‐1))
Study: 20435936
Drug: Propofol (C(blood):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (C(blood): 1.2 microg x mL(‐1))
Study: 18306161
Drug: LED treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED treatments (660 nm)
Study: 16754269
Drug: Candesartan 8‐16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8‐16 mg daily
Study: 10069091
Drug: Hypnotic intervention
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic intervention (individual sessions, audiotapes) designed to augment fracture healing.
Study: 8850384
Drug: Intravenous dopexamine
Normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dopexamine at a rate of 0.5 micrograms/kg/min, titrated to achieve a 30% or more increase in cardiac index
Study: 2209343
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glipizide (20 mg before breakfast and dinner) and human proinsulin (subcutaneously at bedtime)
Study: 2209343
Drug: Glipizide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide (20 mg before breakfast and dinner) and human proinsulin placebo
Study: 7243605
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg peptide analog of ACTH/MSH 4-9
Study: 7243605
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg peptide analog of ACTH/MSH 4-9
Study: 7243605
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg peptide analog of ACTH/MSH 4-9
Study: 7243605
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg peptide analog of ACTH/MSH 4-9 (placebo)
Study: 7243605
Drug: peptide analog
Normalized name: Re188 P2045 somatostatin peptide analogue
DrugBank: P-2045 Re-188 (DB17204)
Approvals — FDA: no, EMA: no, PMDA: no
Description: peptide analog of ACTH/MSH 4-9 (all doses)
Study: 31605549
Drug: COMDQ-15 (short
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMDQ-15 (short version of the Chronic Oral Mucosal Disease Questionnaire)
Study: 27545448
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg once daily until postoperative day 5
Study: 27545448
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin 2000 units twice daily until postoperative day 5
Study: 18211609
Drug: Topical antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antioxidant treatment with vitamin C and alpha-glucosylrutin
Study: 15926437
Drug: Topical fluoride
Normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluoride gel applied prior to acid etching (test group)
Study: 15926437
Drug: Fissure sealant
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fissure sealant applied without prior fluoride treatment (control group)
Study: 12800810
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and moxibustion treatment for six sessions over a 3-week period
Study: 10479134
Drug: MN rgp120
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN rgp120 vaccine
Study: 8759414
Drug: Hydrochlorothiazide (HTZ:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HTZ: 25 mg o.d.)
Study: 8759414
Drug: Propranolol (PRO:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (PRO: 40 mg t.i.d.)
Study: 2862619
Drug: Corynanthine 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynanthine 2% (applied two or three times daily for one, two, or three weeks)
Study: 27306792
Drug: OTL38 (near-infrared
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTL38 (near-infrared fluorescent agent) administered intravenously in increasing doses.
Study: 27306792
Drug: OTL38 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTL38 administered intravenously to patients with ovarian cancer.
Study: 24926548
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m intravenous every 21 days) with PX-866 (8 mg orally daily)
Study: 24926548
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m intravenous every 21 days) without PX-866
Study: 22814125
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (CT) (n=85)
Study: 22814125
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (CT) (n=91)
Study: 15050905
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) for 2-3 years
Study: 12202466
Drug: Risedronate (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (2.5 mg or more)
Study: 11317832
Drug: Tamsulosin 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.8 mg daily
Study: 9789483
Drug: Tamsulosin (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (any dose)
Study: 7502628
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) for up to 12 months followed by combination therapy with HU and human recombinant erythropoietin (rHuEpo; 400 U/kg/week i.v.) for 3-4 weeks.
Study: 7502628
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with HU and rHuEpo
Study: 7046777
Drug: Xipamide 10
Normalized name: xipamide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xipamide 10 mg daily
Study: 7046777
Drug: Xipamide 20
Normalized name: xipamide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xipamide 20 mg daily
Study: 7046777
Drug: Cyclopenthiazide 0.5
Normalized name: cyclopenthiazide 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclopenthiazide 0.5 mg daily
Study: 20004779
Drug: Early therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early therapy with inhaled corticosteroid (ICS) budesonide for 2 years
Study: 20004779
Drug: Delayed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed therapy with inhaled corticosteroid (ICS) budesonide after 2 years of terbutaline treatment
Study: 17312235
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ropivacaine and clonidine (block group)
Study: 15257093
Drug: L‐NAME treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NAME treatment
Study: 7946580
Drug: Information on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information on proposed treatment arm only
Study: 1762806
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of epidural morphine
Study: 1762806
Drug: Repeated bolus
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated bolus doses of epidural morphine
Study: 26427111
Drug: Votalin, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Votalin, 75 mg, once a day for 8 weeks
Study: 19009458
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day of vitamin C for 14 days
Study: 19009458
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg ascorbate after a 7-14 day non-intervention period
Study: 19009458
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ascorbate dosage regimen
Study: 19009458
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ascorbate dosage regimen
Study: 19009458
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg ascorbate dosage regimen
Study: 11590482
Drug: VC-1500 (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC-1500 (1500 mg/day Vitamin C)
Study: 11590482
Drug: VC-500 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC-500 (500 mg/day Vitamin C)
Study: 9533371
Drug: 200 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/kg of Curosurf via dual-lumen endotracheal tube
Study: 9533371
Drug: 200 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/kg of Curosurf via bolus instillation
Study: 2962478
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator, percutaneous coronary angioplasty, or both
Study: 28341958
Drug: Docetaxel/cisplatin (DP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel/cisplatin (DP) - docetaxel (35 mg/m2)/cisplatin (30 mg/m2) iv on days 1 and 8, every 3 weeks.
Study: 28341958
Drug: Gemcitabine/cisplatin (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine/cisplatin (GP) - gemcitabine (1000 mg/m2)/cisplatin (30 mg/m2) iv on days 1 and 8, every 3 weeks.
Study: 22271372
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate (300 mg/day)
Study: 22271372
Drug: Amitriptyline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (10 mg/day)
Study: 22271372
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate (300 mg/day) + Amitriptyline (10 mg/day)
Study: 21693570
Drug: DM self
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DM self management programme (experimental group) - six sessions of weekly course
Study: 16247249
Drug: R126638 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: R126638 100 mg
Study: 16247249
Drug: R126638 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: R126638 200 mg
Study: 11115305
Drug: Glycopyrrolate (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (0.10 mg/kg per dose)
Study: 1622977
Drug: Parboiled white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parboiled white rice (25 g carbohydrate)
Study: 1622977
Drug: Parboiled white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parboiled white rice (50 g carbohydrate)
Study: 1622977
Drug: White bread
Normalized name: White bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: White bread (25 g carbohydrate)
Study: 1622977
Drug: White bread
Normalized name: White bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: White bread (50 g carbohydrate)
Study: 3924748
Drug: Omeprazole (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (0.35 mg/kg)
Study: 10812285
Drug: THC (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (7.5 mg)
Study: 22356757
Drug: Fallopian tube
Normalized name: SUS SCROFA FALLOPIAN TUBE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fallopian tube sperm perfusion (FSP) via Foley catheter with 4 mL of inseminate
Study: 22356757
Drug: Standard intrauterine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intrauterine insemination (IUI) with 0.5 mL of inseminate
Study: 18058480
Drug: diuretics
Normalized name: DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: diuretics
Study: 10089853
Drug: Biventricular pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biventricular pacing therapy
Study: 10089853
Drug: No pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pacing therapy (control)
Study: 10089853
Drug: Biventricular pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biventricular pacing therapy (with ICD)
Study: 2404806
Drug: Progesterone supplementation
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone supplementation of 100 mg/day, initiated 10 hours before hCG administration and continued for 6 days.
Study: 7370145
Drug: Meptazinol 60
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol 60 mg
Study: 19054806
Drug: Sequential Organ
Normalized name: argan oil
DrugBank: Argan oil (DB14310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Organ Failure Assessment
Study: 15351854
Drug: Recombinant urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant urokinase (r-UK) 5000 IU/ml
Study: 9684393
Drug: Daily buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily buprenorphine (8 mg)
Study: 9684393
Drug: Alternate-day dosing
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day dosing of buprenorphine and placebo
Study: 2547138
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg piperazine oestrone sulphate
Study: 2547138
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg piperazine oestrone sulphate + 5.0 mg oestriol
Study: 2547138
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg oestradiol valerate
Study: 2547138
Drug: 10.0 mg
Normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.0 mg oestriol
Study: 2547138
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with 250 micrograms of levonorgestrel
Study: 2547138
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration for a week